Systematic development of novel peptide-derived therapeutics for the inhibition of lysine-modifying enzymes for the treatment of cancer

Cancer will affect 2 in every 5 Canadians in their lifetime, with just over 25% representing new breast cancer diagnoses in women. Despite significant progress in the treatment of the most common cancer in women, resistance to chemotherapeutic agents remains a consistent obstacle in terms of the successful treatment of many types of breast cancers. […]

Read More